echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Key varieties of Yuandong biological science and Technology Innovation Board will face the "pressure mountain" of national centralized mining

    Key varieties of Yuandong biological science and Technology Innovation Board will face the "pressure mountain" of national centralized mining

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Wen Fengqiu < br / > on June 10, the official website of science and Technology Innovation Board of Shanghai Stock Exchange disclosed that Chengdu Yuandong biopharmaceutical Co., Ltdhad a successful meeting, and the company planned to raise 1.161 billion yuan in science and technology innovation board< br / > Yuandong biology plans to raise 1.161 billion yuan this time for the construction of industrialization base of innovative drug series products in major disease field, drug clinical research project, biological drug R & D project, marketing network construction project, innovation capacity construction project of Technology Center, information system construction project and supplementary working capitalThe specific raised funds and their uses are as follows: < br / > as disclosed in the prospectus, Chengdu Yuandong Biological Technology Co., Ltdplans to adopt the first set of listing standards in science and Technology Innovation Board of Shanghai Stock Exchange, i.ethe expected market value is not less than 1 billion yuan, the net profits in the last two years are all positive and the accumulated net profits are not less than 50 million yuan, or the expected market value is not less than 1 billion yuan, The net profit of the latest year is positive and the operating revenue is no less than RMB 100 million< br / > according to the public information, Chengdu Yuandong Bio Technology Co., Ltdis a high-tech enterprise driven by R & D and innovation, mainly engaged in the R & D, production and sales of chemical APIs and chemical pharmaceutical preparationsIt has the production capacity of various dosage forms and chemical APIs such as injection, freeze-dried powder injection, tablet, capsule, etc., and has been deployed in the field of bio pharmaceuticalsDuring the reporting period, the company's main products were chemical generic drugs, and its operating revenue also mainly came from the sales of generic drugsHowever, the sales expense of Chengdu Yuandong Bio Technology Co., Ltdaccounts for a relatively high proportion of the current operating revenue, which is far greater than the R & D expense, more than three times of the R & D expenseIn the composition of sales expenses, the promotion service fee is the highest, accounting for more than 90% in the reporting period< br / > there are 3 domestic first imitated products in Chengdu Yuandong biological Co., Ltd., 4 products passing the consistency evaluation, 2 of which are the first products passing the consistency evaluationDuring the reporting period, the company's main product income, the proportion of income from the first imitated product and the product passing the consistency evaluation are as follows: < br / > < br / > < br / / > many drugs under research are still in the clinical trial stage, as follows: < br / > in the prospectus of the last meeting, Chengdu Yuandong biology also mentioned the impact of drug collection on it, and its bisoprolol fumarate tablets won the second batch of drug centralized procurement, The bidding price of this time is: 2.5mg 6.15 yuan / box, 5mg 10.46 yuan / box, the average drop rate is 69% compared with that before centralized drug procurementIn the first year of the selected province, the agreed purchase volume is 5 mg, 122.9931 million tablets, and 2.5 mg, 21.2952 million tabletsAccording to the sales situation from January to April 2020, bisoprolol fumarate tablets achieved sales of 124.406 million tablets (equivalent to 5mg), which has completed 63% of the annual sales last year As the price of bisoprolol fumarate tablets is significantly lower than before, it is expected that the sales revenue in 2020 will be lower than that in 2019; after the centralized purchase of drugs, the company will reduce the marketing expenses of the product, and the impact of the price drop on the operating profit is relatively small Therefore, according to the company's sensitivity analysis and calculation results, if the company's sales volume of bisoprolol fumarate tablets does not reach 10% year-on-year growth in 2020, the company's operating profit of the product will decline year-on-year, which will have a negative impact on the company's operation < br / > in addition, Chengdu Yuandong biology is also faced with the risks brought by the adjustment of the medical insurance catalog to its main pharmaceutical products In 2019, ubenimese capsule products were transferred out of the national medical insurance catalog, and the sales revenue of the products in the reporting period was 124510600 yuan, 205212800 yuan, 202916400 yuan, accounting for 26.25%, 26.72%, 21.53% respectively, As the national medical insurance catalogue in 2019 is implemented from 2020, the sales revenue of ubenimex capsule in January April 2020 is 45.86% lower than that in the same period of 2019
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.